



## Antibody Research in the COVID-19 Pandemic

Guest Editor:

### Dr. Surender Khurana

Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD 20993, USA

Deadline for manuscript submissions:

**closed (31 January 2024)**

### Message from the Guest Editor

Dear Colleagues,

The COVID-19 pandemic shook the world globally with dreadful implications, but also demonstrated an unprecedented collective response to the SARS-CoV-2 infection. To address global public health, this Special Issue will discuss the methods and approaches to illustrate and profile the immune response following infection and vaccination.

We would like to invite you to share your work on vaccines and/or infection (both COVID-19 and other diseases), with an emphasis on immune response studies.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- The antibody response following vaccination.
- Immune response following infection.
- Role of number and dosage of vaccination in immune response.
- The safety of vaccines.
- Impact of monovalent vs bivalent vaccines.
- Circulating and emerging SARS-CoV-2 variants.

We look forward to receiving your contributions.

Dr. Surender Khurana  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)